JP2014158469A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014158469A5 JP2014158469A5 JP2014043403A JP2014043403A JP2014158469A5 JP 2014158469 A5 JP2014158469 A5 JP 2014158469A5 JP 2014043403 A JP2014043403 A JP 2014043403A JP 2014043403 A JP2014043403 A JP 2014043403A JP 2014158469 A5 JP2014158469 A5 JP 2014158469A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- antibody according
- variable region
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 14
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 150000001413 amino acids Chemical class 0.000 claims 5
- 101000872077 Homo sapiens Delta-like protein 4 Proteins 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 102000044457 human DLL4 Human genes 0.000 claims 4
- 239000002157 polynucleotide Substances 0.000 claims 4
- 102000040430 polynucleotide Human genes 0.000 claims 4
- 108091033319 polynucleotide Proteins 0.000 claims 4
- 230000004614 tumor growth Effects 0.000 claims 4
- 108700041286 delta Proteins 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 101100499372 Homo sapiens DLL1 gene Proteins 0.000 claims 1
- 101000928513 Homo sapiens Delta-like protein 3 Proteins 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 101100387419 Mus musculus Dll4 gene Proteins 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 102000053255 human DLL3 Human genes 0.000 claims 1
- 210000004408 hybridoma Anatomy 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000004898 n-terminal fragment Anatomy 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 230000009870 specific binding Effects 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US84790406P | 2006-09-29 | 2006-09-29 | |
| US60/847,904 | 2006-09-29 | ||
| US88626007P | 2007-01-23 | 2007-01-23 | |
| US60/886,260 | 2007-01-23 | ||
| US94254207P | 2007-06-07 | 2007-06-07 | |
| US60/942,542 | 2007-06-07 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009530419A Division JP5535633B2 (ja) | 2006-09-29 | 2007-09-28 | 癌の診断および処置のための組成物および方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016164264A Division JP2017002076A (ja) | 2006-09-29 | 2016-08-25 | 癌の診断および処置のための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014158469A JP2014158469A (ja) | 2014-09-04 |
| JP2014158469A5 true JP2014158469A5 (enExample) | 2014-10-16 |
| JP5997194B2 JP5997194B2 (ja) | 2016-09-28 |
Family
ID=39268983
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009530419A Expired - Fee Related JP5535633B2 (ja) | 2006-09-29 | 2007-09-28 | 癌の診断および処置のための組成物および方法 |
| JP2014043403A Expired - Fee Related JP5997194B2 (ja) | 2006-09-29 | 2014-03-06 | 癌の診断および処置のための組成物および方法 |
| JP2016164264A Pending JP2017002076A (ja) | 2006-09-29 | 2016-08-25 | 癌の診断および処置のための組成物および方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009530419A Expired - Fee Related JP5535633B2 (ja) | 2006-09-29 | 2007-09-28 | 癌の診断および処置のための組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016164264A Pending JP2017002076A (ja) | 2006-09-29 | 2016-08-25 | 癌の診断および処置のための組成物および方法 |
Country Status (27)
| Country | Link |
|---|---|
| US (5) | US7750124B2 (enExample) |
| EP (3) | EP2562188A3 (enExample) |
| JP (3) | JP5535633B2 (enExample) |
| KR (1) | KR101477824B1 (enExample) |
| AU (1) | AU2007305443B2 (enExample) |
| BR (1) | BRPI0717431A2 (enExample) |
| CA (1) | CA2664738C (enExample) |
| CO (1) | CO6180466A2 (enExample) |
| CR (1) | CR10667A (enExample) |
| CY (1) | CY1117154T1 (enExample) |
| DK (1) | DK2066694T3 (enExample) |
| EA (1) | EA018260B1 (enExample) |
| ES (1) | ES2557953T3 (enExample) |
| HR (1) | HRP20160082T1 (enExample) |
| HU (1) | HUE028379T2 (enExample) |
| IL (1) | IL197721A (enExample) |
| MA (1) | MA30808B1 (enExample) |
| ME (1) | ME02371B (enExample) |
| MX (1) | MX2009003229A (enExample) |
| NO (1) | NO20091635L (enExample) |
| NZ (1) | NZ576404A (enExample) |
| PL (1) | PL2066694T3 (enExample) |
| PT (1) | PT2066694E (enExample) |
| RS (1) | RS54452B1 (enExample) |
| SI (1) | SI2066694T1 (enExample) |
| WO (1) | WO2008042236A2 (enExample) |
| ZA (1) | ZA200901615B (enExample) |
Families Citing this family (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7906116B2 (en) * | 2005-09-01 | 2011-03-15 | Parkash Gill | Methods for using and identifying modulators of Delta-like 4 |
| PL2032166T3 (pl) * | 2006-06-13 | 2013-09-30 | Oncomed Pharm Inc | Kompozycje i sposoby diagnozowania i leczenia nowotworów |
| US7750124B2 (en) | 2006-09-29 | 2010-07-06 | Oncomed Pharmaceuticals, Inc. | Anti-human DLL4 antibodies and compositions |
| NO347649B1 (no) | 2006-12-14 | 2024-02-12 | Regeneron Pharma | Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse. |
| JP5618544B2 (ja) | 2007-01-24 | 2014-11-05 | オンコメッドファーマシューティカルズ インコーポレイテッド | 癌の診断および処置のための組成物および方法 |
| US20100119526A1 (en) * | 2007-01-26 | 2010-05-13 | Bioinvent International Ab | DLL4 Signaling Inhibitors and Uses Thereof |
| GB0709333D0 (en) * | 2007-05-15 | 2007-06-20 | Smart Targeting Ltd | Binding protein |
| JP5931336B2 (ja) | 2007-07-02 | 2016-06-08 | オンコメッド ファーマシューティカルズ インコーポレイテッド | がんを処置および診断するための組成物および方法 |
| US8119366B2 (en) * | 2007-10-05 | 2012-02-21 | Trojan Technologies, Ltd. | Antennapedia-dominant negative mastermind-like construct |
| CN102076355B (zh) | 2008-04-29 | 2014-05-07 | Abbvie公司 | 双重可变结构域免疫球蛋白及其用途 |
| CN105467136B (zh) * | 2008-05-30 | 2018-02-16 | 埃克斯生物科技公司 | 白细胞介素‑1α抗体及使用方法 |
| AU2009256246B2 (en) | 2008-06-03 | 2013-07-18 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
| SG191639A1 (en) | 2008-06-03 | 2013-07-31 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| US8834875B2 (en) | 2010-01-13 | 2014-09-16 | Oncomed Pharmaceuticals, Inc. | Notch1 binding agents and methods of use thereof |
| AU2009268585C1 (en) | 2008-07-08 | 2014-10-02 | Abbvie Inc. | Prostaglandin E2 dual variable domain immunoglobulins and uses thereof |
| CN102316897B (zh) | 2008-07-08 | 2014-11-05 | 昂考梅德药品有限公司 | Notch结合剂和拮抗剂及其应用方法 |
| US9132189B2 (en) | 2008-07-08 | 2015-09-15 | Oncomed Pharmaceuticals, Inc. | Notch1 binding agents and methods of use thereof |
| US8652843B2 (en) | 2008-08-12 | 2014-02-18 | Oncomed Pharmaceuticals, Inc. | DDR1-binding agents and methods of use thereof |
| MX2011002837A (es) * | 2008-09-19 | 2011-07-29 | Medimmune Llc | Anticuerpos dirigidos al ligando tipo delta 4 (dll4) y usos de los mismos. |
| DK2842573T3 (en) | 2008-11-07 | 2017-10-30 | Galaxy Biotech Llc | Monoclonal antibodies to fibroblast growth factor receptor 2 |
| EP2356270B1 (en) * | 2008-11-07 | 2016-08-24 | Fabrus Llc | Combinatorial antibody libraries and uses thereof |
| CN102459346B (zh) | 2009-04-27 | 2016-10-26 | 昂考梅德药品有限公司 | 制造异源多聚体分子的方法 |
| TWI513465B (zh) * | 2009-06-25 | 2015-12-21 | Regeneron Pharma | 以ｄｌｌ４拮抗劑與化學治療劑治療癌症之方法 |
| PE20121647A1 (es) | 2009-08-29 | 2012-12-31 | Abbvie Inc | Proteinas terapeuticas de union a dll4 |
| TW201119673A (en) | 2009-09-01 | 2011-06-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| UY32948A (es) | 2009-10-15 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| EP3485908B1 (en) * | 2009-10-16 | 2021-08-18 | Mereo BioPharma 5, Inc. | Therapeutic combination and use of dll4 antagonist antibodies and anti-hypertensive agents |
| UY32979A (es) | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| US8945569B2 (en) | 2009-11-19 | 2015-02-03 | Oncomed Pharmaceuticals, Inc. | Jagged-binding agents and uses thereof |
| WO2011068840A1 (en) * | 2009-12-01 | 2011-06-09 | Oncomed Pharmaceuticals, Inc. | Methods for treating cancers comprising k-ras mutations |
| TWI535445B (zh) | 2010-01-12 | 2016-06-01 | 安可美德藥物股份有限公司 | Ｗｎｔ拮抗劑及治療和篩選方法 |
| JO3183B1 (ar) | 2010-01-29 | 2018-03-08 | Regeneron Pharma | طرق لمعالجة أمراض المناعة الذاتية مضادات dll4 |
| CN103237901B (zh) | 2010-03-01 | 2016-08-03 | 卡里斯生命科学瑞士控股有限责任公司 | 用于治疗诊断的生物标志物 |
| SG10201501562VA (en) | 2010-03-02 | 2015-04-29 | Abbvie Inc | Therapeutic dll4 binding proteins |
| CA2795776A1 (en) | 2010-04-06 | 2011-10-13 | Caris Life Sciences Luxembourg Holdings, S.A.R.L. | Circulating biomarkers for disease |
| TW201206473A (en) | 2010-08-03 | 2012-02-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| WO2012024543A1 (en) * | 2010-08-18 | 2012-02-23 | Caris Life Sciences Luxembourg Holdings | Circulating biomarkers for disease |
| CN103260639A (zh) | 2010-08-26 | 2013-08-21 | Abbvie公司 | 双重可变结构域免疫球蛋白及其用途 |
| US8551479B2 (en) | 2010-09-10 | 2013-10-08 | Oncomed Pharmaceuticals, Inc. | Methods for treating melanoma |
| US20130323265A1 (en) * | 2010-11-15 | 2013-12-05 | Oncomed Pharmaceuticals, Inc. | Methods for treating cancer with dll4 antagonists |
| WO2012092539A2 (en) | 2010-12-31 | 2012-07-05 | Takeda Pharmaceutical Company Limited | Antibodies to dll4 and uses thereof |
| AU2012235767B2 (en) * | 2011-03-27 | 2016-02-04 | Oncostem Diagnostics (Mauritius) Pvt. Ltd. | Markers for identifying tumor cells, methods and kit thereof |
| CA2838973A1 (en) * | 2011-06-17 | 2012-12-20 | Adrian L. Harris | Methods of enhancing the response to radiation in tumor therapy using anti-dll4 antibodies |
| CN106167526A (zh) | 2011-07-15 | 2016-11-30 | 昂考梅德药品有限公司 | Rspo结合剂和其应用 |
| WO2013039954A1 (en) * | 2011-09-14 | 2013-03-21 | Sanofi | Anti-gitr antibodies |
| HRP20190044T1 (hr) * | 2011-09-23 | 2019-02-22 | Oncomed Pharmaceuticals, Inc. | Agensi koji vežu vegf/dll4 i njihove uporabe |
| WO2013102042A2 (en) | 2011-12-30 | 2013-07-04 | Abbvie Inc. | Dual specific binding proteins directed against il-13 and/or il-17 |
| JP2015520172A (ja) * | 2012-05-31 | 2015-07-16 | ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | Ｄｌｌ−４に結合する抗原結合蛋白質 |
| WO2013184912A2 (en) | 2012-06-06 | 2013-12-12 | Oncomed Pharmaceuticals, Inc. | Binding agents that modulate the hippo pathway and uses thereof |
| CA2878868A1 (en) | 2012-07-13 | 2014-01-16 | Austin L. Gurney | Rspo3 binding agents and uses thereof |
| PL3489261T3 (pl) | 2012-08-24 | 2021-08-16 | The Regents Of The University Of California | Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu |
| WO2014062659A2 (en) * | 2012-10-15 | 2014-04-24 | Oncomed Pharmaceuticals, Inc. | Methods of treating ocular diseases |
| AU2013337811A1 (en) * | 2012-10-31 | 2015-05-14 | Oncomed Pharmaceuticals, Inc. | Methods and monitoring of treatment with a DLL4 antagonist |
| HK1212359A1 (en) | 2012-11-01 | 2016-06-10 | Abbvie Inc. | Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof |
| AR093445A1 (es) | 2012-11-14 | 2015-06-10 | Regeneron Pharma | Metodos para tratar el cancer de ovario con antagonistas de dll4 |
| US9327014B2 (en) | 2012-12-04 | 2016-05-03 | Oncomed Pharmaceuticals, Inc. | Immunotherapy with binding agents |
| JP6449537B2 (ja) * | 2012-12-27 | 2019-01-09 | 日本メジフィジックス株式会社 | 抗腫瘍剤、及び、抗腫瘍用キット |
| JP2016522793A (ja) | 2013-03-15 | 2016-08-04 | アッヴィ・インコーポレイテッド | ＩＬ−１βおよび／またはＩＬ−１７に対して指向された二重特異的結合タンパク質 |
| GB201312727D0 (en) * | 2013-07-16 | 2013-08-28 | Isis Innovation | Modulators |
| PE20160190A1 (es) | 2013-08-01 | 2016-04-28 | Five Prime Therapeutics Inc | Anticuerpos anti-fgfr2iiib afucosilados |
| MX2016007066A (es) | 2013-12-02 | 2016-09-08 | Oncomed Pharm Inc | Identificacion de marcadores biologicos predictivos asociados con inhibidores de la via de wnt. |
| JPWO2015108203A1 (ja) | 2014-01-15 | 2017-03-23 | 株式会社オーダーメードメディカルリサーチ | 抗ｓｌｃ６ａ６抗体を用いたがん治療用医薬組成物 |
| DK3172227T3 (da) * | 2014-07-21 | 2019-12-02 | Delinia Inc | Molekyler der selektivt aktiverer regulatoriske t-celler til behandlingen af autoimmune sygdomme |
| EP3193935A4 (en) | 2014-09-16 | 2018-03-21 | Oncomed Pharmaceuticals, Inc. | Treatment of fibrotic diseases |
| MX382902B (es) | 2014-10-31 | 2025-03-13 | Oncomed Pharm Inc | Inhibidor de la vía noth en combinación con un agente inmunoterapéutico para usarse en el tratamiento de cáncer. |
| WO2016094881A2 (en) | 2014-12-11 | 2016-06-16 | Abbvie Inc. | Lrp-8 binding proteins |
| TWI715587B (zh) | 2015-05-28 | 2021-01-11 | 美商安可美德藥物股份有限公司 | Ｔｉｇｉｔ結合劑和彼之用途 |
| TW201710286A (zh) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白 |
| WO2017053705A1 (en) | 2015-09-23 | 2017-03-30 | Oncomed Pharmaceuticals, Inc. | Methods and compositions for treatment of cancer |
| BR112018010410A8 (pt) | 2015-11-23 | 2019-02-26 | Five Prime Therapeutics Inc | método para tratar câncer em um sujeito, composição e métodos de aumento do número de células nk e de aumento do número de uma ou mais células positivas para pd-l1 |
| US20170204154A1 (en) | 2016-01-20 | 2017-07-20 | Delinia, Inc. | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
| CN114191067B (zh) | 2016-05-19 | 2024-12-17 | 圣安娜技术有限公司 | 具有双囊结构以对组织产生并施加消融区域的导管 |
| WO2017205651A1 (en) * | 2016-05-25 | 2017-11-30 | The Trustees Of Columbia University In The City Of New York | Human notch1 based fusion proteins as decoy inhibitors of jagged-notch signaling and dll-notch signaling |
| CA3029003A1 (en) | 2016-06-27 | 2018-01-04 | The Regents Of The University Of California | Cancer treatment combinations |
| JP7500195B2 (ja) | 2016-08-23 | 2024-06-17 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | タンパク質分解により切断可能なキメラポリペプチド及びそれらの使用方法 |
| EP3515491A4 (en) | 2016-09-21 | 2020-09-16 | Aptevo Research and Development LLC | CD123 BINDING PROTEINS AND RELATED COMPOSITIONS AND PROCESSES |
| CN110167957A (zh) | 2016-11-08 | 2019-08-23 | 德里尼亚公司 | 用于治疗自身免疫疾病的il-2变体 |
| US11230596B2 (en) | 2016-11-30 | 2022-01-25 | Mereo Biopharma 5, Inc. | Methods for treatment of cancer comprising TIGIT-binding agents |
| CN110621336B (zh) | 2017-05-16 | 2024-05-14 | 戊瑞治疗有限公司 | 癌症治疗中抗fgfr2抗体与化学治疗剂的组合 |
| EP3801324B1 (en) | 2018-06-01 | 2025-05-28 | Aqua Medical, Inc. | Vapor generation and delivery systems |
| CN113015495A (zh) | 2018-09-11 | 2021-06-22 | 阿卡赫特有限公司 | 用于治疗心脏疾病的加热蒸汽消融系统和方法 |
| AU2019380595A1 (en) | 2018-11-15 | 2021-06-03 | Oncomed Pharmaceuticals, Inc. | Methods and monitoring of treatment with VEGF/DLL4 binding agent |
| US20210059749A1 (en) | 2019-08-28 | 2021-03-04 | Santa Anna Tech Llc | Systems and Methods for Ablating Prostate Tissue |
| WO2021146526A1 (en) | 2020-01-15 | 2021-07-22 | Aqua Medical, Inc. | Vapor ablation system with simplified control over vapor delivery |
| EP4225180A4 (en) | 2020-10-08 | 2024-10-30 | Santa Anna Tech LLC | VISUALIZATION-CAPABLE ABLATION CATHETERS, SYSTEMS AND PROCEDURES |
| WO2023149977A1 (en) * | 2022-02-04 | 2023-08-10 | Mereo Biopharma 5, Inc. | Methods for treating cancer |
Family Cites Families (131)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| FR2248608B1 (enExample) * | 1973-10-17 | 1977-05-27 | Labo Electronique Physique | |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4588585A (en) | 1982-10-19 | 1986-05-13 | Cetus Corporation | Human recombinant cysteine depleted interferon-β muteins |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| WO1992009690A2 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
| US6582959B2 (en) * | 1991-03-29 | 2003-06-24 | Genentech, Inc. | Antibodies to vascular endothelial cell growth factor |
| IL101728A (en) | 1991-05-03 | 2007-08-19 | Univ Yale | Human Abandonment and Delta, Restrictive Areas of Effect in Tophoric Proteins, and Methods Based on Them |
| US5786158A (en) | 1992-04-30 | 1998-07-28 | Yale University | Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids |
| US20050112121A1 (en) * | 1992-04-30 | 2005-05-26 | Yale University | Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids |
| US5840299A (en) | 1994-01-25 | 1998-11-24 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| EP0861261B9 (en) * | 1995-06-28 | 2010-02-24 | Imperial Cancer Research Technology Limited | Nucleotide and protein sequences of vertebrate delta genes and methods based thereon |
| US5730977A (en) * | 1995-08-21 | 1998-03-24 | Mitsui Toatsu Chemicals, Inc. | Anti-VEGF human monoclonal antibody |
| JPH09124697A (ja) * | 1995-11-01 | 1997-05-13 | Toagosei Co Ltd | ペプチド及びモノクローナル抗体 |
| DE69635899T2 (de) | 1995-11-17 | 2006-11-23 | Asahi Kasei Kabushiki Kaisha | Polypeptid, das die differenzierung unterdrueckt |
| US20020137890A1 (en) * | 1997-03-31 | 2002-09-26 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US6121045A (en) * | 1997-04-04 | 2000-09-19 | Millennium Biotherapeutics, Inc. | Human Delta3 nucleic acid molecules |
| EP0972041B2 (en) | 1997-04-04 | 2017-01-18 | Millennium Pharmaceuticals, Inc. | Novel human delta3 compositions and therapeutic and diagnostic uses therefor |
| US20030180784A1 (en) * | 1997-04-04 | 2003-09-25 | Millennium Pharmaceuticals, Inc. | Novel human Delta3 compositions and therapeutic and diagnostic uses therefor |
| US20060122373A1 (en) * | 1997-04-04 | 2006-06-08 | Millennium Pharmaceuticals, Inc. | Delta3, FTHMA-070, Tango85, Tango77, SPOIL,NEOKINE, Tango129 and integrin alpha subunit protein and nucleic acid molecules and uses thereof |
| US20020032315A1 (en) * | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| US20070059302A1 (en) * | 1997-04-07 | 2007-03-15 | Genentech, Inc. | Anti-vegf antibodies |
| ES2236634T3 (es) * | 1997-04-07 | 2005-07-16 | Genentech, Inc. | Anticuerpos anti-vegf. |
| CA2288343A1 (en) | 1997-04-25 | 1998-11-05 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
| EP0979281B1 (en) | 1997-05-02 | 2005-07-20 | Genentech, Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
| US20020062010A1 (en) * | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| US7951917B1 (en) * | 1997-05-02 | 2011-05-31 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| WO1998051799A1 (en) * | 1997-05-14 | 1998-11-19 | Asahi Kasei Kogyo Kabushiki Kaisha | Novel differentiation inhibitor |
| WO1998057621A1 (en) | 1997-06-18 | 1998-12-23 | The Trustees Of Columbia University In The City Ofnew York | Angiogenic modulation by notch signal transduction |
| US6004528A (en) * | 1997-09-18 | 1999-12-21 | Bergstein; Ivan | Methods of cancer diagnosis and therapy targeted against the cancer stemline |
| EP1100899A2 (en) | 1998-07-27 | 2001-05-23 | Amgen Inc. | Delta-related polypeptides |
| CN1308347C (zh) * | 1999-04-28 | 2007-04-04 | 德克萨斯大学董事会 | 用于通过选择性抑制vegf来治疗癌症的组合物和方法 |
| JP4723140B2 (ja) | 1999-06-08 | 2011-07-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 改善された薬物動態特性を有する改変キメラポリペプチド |
| WO2001007611A2 (en) | 1999-07-26 | 2001-02-01 | Genentech, Inc. | Novel polynucleotides and method for the use thereof |
| EP1686134A3 (en) | 1999-12-01 | 2006-08-09 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| AU5904101A (en) | 2000-04-05 | 2001-10-23 | Hyseq Inc | Methods and materials relating to novel stem cell growth factor-like polypeptides and polynucleotides |
| US20110131679A2 (en) * | 2000-04-19 | 2011-06-02 | Thomas La Rosa | Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement |
| GB0014185D0 (en) * | 2000-06-09 | 2000-08-02 | Novartis Res Found | Compound and method |
| US20020028488A1 (en) * | 2000-06-19 | 2002-03-07 | Sujay Singh | Transgenic avian species for making human and chimeric antibodies |
| US6984522B2 (en) * | 2000-08-03 | 2006-01-10 | Regents Of The University Of Michigan | Isolation and use of solid tumor stem cells |
| US6689744B2 (en) * | 2000-09-22 | 2004-02-10 | Genentech, Inc. | Notch receptor agonists and uses |
| US7667004B2 (en) * | 2001-04-17 | 2010-02-23 | Abmaxis, Inc. | Humanized antibodies against vascular endothelial growth factor |
| EP1410018A1 (en) * | 2001-07-25 | 2004-04-21 | Lorantis Limited | Method for detecting modultators of notch signalling |
| JP4689956B2 (ja) * | 2001-08-01 | 2011-06-01 | ユニバーシティ オブ ブリストル | 増殖因子イソ型 |
| EP1446424A2 (en) * | 2001-11-14 | 2004-08-18 | Lorantis Limited | Composition comprising inhibitors of the notch signalling pathway for the modulation of the immune system |
| US20050137130A1 (en) * | 2001-11-14 | 2005-06-23 | Bodmer Mark W. | Medical treatment |
| JP2005526701A (ja) * | 2001-11-14 | 2005-09-08 | ロランティス リミテッド | 内科療法 |
| CA2469204A1 (en) * | 2001-12-07 | 2003-06-19 | Regents Of The University Of Michigan | Prospective identification and characterization of breast cancer stem cells |
| US8034904B2 (en) | 2002-06-14 | 2011-10-11 | Immunogen Inc. | Anti-IGF-I receptor antibody |
| GB0218879D0 (en) * | 2002-08-14 | 2002-09-25 | Lorantis Ltd | Medical treatment |
| EP1537145A1 (en) * | 2002-09-10 | 2005-06-08 | Lorantis Limited | Pharmaceutical compositions and medical treatments comprising notch ligand proteins |
| US7354578B2 (en) | 2003-06-06 | 2008-04-08 | Regeneron Pharmaceuticals, Inc. | Method of tumor regression with VEGF inhibitors |
| US20050106667A1 (en) | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
| US7758859B2 (en) * | 2003-08-01 | 2010-07-20 | Genentech, Inc. | Anti-VEGF antibodies |
| JP4818917B2 (ja) * | 2003-08-08 | 2011-11-16 | イミューノメディクス、インコーポレイテッド | 腫瘍および罹患細胞のアポトーシスを誘発するための二重特異性抗体 |
| FR2859725B1 (fr) * | 2003-09-16 | 2006-03-10 | Neovacs | Procede a haut rendement pour l'obtention d'anticorps humains neutralisant l'activite biologique d'une cytokine humaine |
| EP2583685A1 (en) | 2004-06-10 | 2013-04-24 | Regeneron Pharmaceuticals, Inc. | Method of administering and using VEGF inhibitors for the treatment of human cancer |
| EP1755645A2 (en) | 2004-06-18 | 2007-02-28 | Regeneron Pharmaceuticals, Inc. | Vegf inhibitors for the treatment of malignant pleural effusion |
| CA2577082A1 (en) | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Heteromultimeric molecules |
| US20080254031A1 (en) | 2004-09-09 | 2008-10-16 | Exonhit Therapeutics Sa | Tumor Specific Genes and Variant Rnas and Uses Thereof as Targets for Cancer Therapy and Diagnosis |
| EP1810979B1 (en) | 2004-09-22 | 2012-06-20 | Kyowa Hakko Kirin Co., Ltd. | STABILIZED HUMAN IgG4 ANTIBODIES |
| US8048418B2 (en) * | 2004-10-29 | 2011-11-01 | Regeneron Pharmaceuticals, Inc. | Therapeutic methods for inhibiting tumor growth with combination of Dll4 antagonists and VEGF antagonists |
| US20060134121A1 (en) * | 2004-10-29 | 2006-06-22 | Gavin Thurston | DII4 antagonists, assays, and therapeutic methods thereof |
| RU2392961C2 (ru) | 2004-11-10 | 2010-06-27 | Хубрехт Лабораториум | Лечение аденомы и/или аденокарциномы кишечника с помощью ингибирования активации пути notch |
| WO2006083355A2 (en) * | 2004-11-19 | 2006-08-10 | Cornell Research Foundation, Inc. | Use of vascular endothelial growth factor receptor 1+ cells in treating and monitoring cancer and in screening for chemotherapeutics |
| US7432107B2 (en) | 2005-01-24 | 2008-10-07 | Roche Diagnostics Operations, Inc. | Cardiac hormones for assessing cardiovascular risk |
| EP1853298A2 (en) | 2005-02-11 | 2007-11-14 | Regeneron Pharmaceuticals, Inc. | Therapeutic combination of a vegf antagonist (vegf trap) and an anti-hypertensive agent |
| JP5620626B2 (ja) | 2005-03-31 | 2014-11-05 | 中外製薬株式会社 | 会合制御によるポリペプチド製造方法 |
| AU2006236439B2 (en) * | 2005-04-15 | 2012-05-03 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| JP2008545753A (ja) * | 2005-06-02 | 2008-12-18 | ギャラクシー バイオテック， エルエルシー | 抗体で脳腫瘍を処置する方法 |
| MX2008001966A (es) | 2005-08-12 | 2008-03-26 | Regeneron Pharma | Tratamiento de enfermedades mediante administracion subcutanea de un antagonista vegf. |
| WO2007028110A2 (en) * | 2005-09-01 | 2007-03-08 | Vasgene Therapeutics, Inc. | Methods for using and identifying modulators of delta-like 4 |
| US7906116B2 (en) * | 2005-09-01 | 2011-03-15 | Parkash Gill | Methods for using and identifying modulators of Delta-like 4 |
| DK1962895T3 (da) * | 2005-12-16 | 2013-03-04 | Regeneron Pharma | TERAPEUTISK ANVENDELSE AF EN Dll4-ANTAGONIST OG EN VEGF-HÆMMER TIL HÆMNING AF TUMORVÆKST |
| US20090221549A1 (en) | 2006-02-17 | 2009-09-03 | Gilead Colorado, Inc. | Antihypertensive therapy |
| US7354582B2 (en) * | 2006-03-10 | 2008-04-08 | Regeneron Pharmaceuticals, Inc. | Use of VEGF antagonists for the treatment of malignant gliomas |
| WO2007110205A2 (en) | 2006-03-24 | 2007-10-04 | Merck Patent Gmbh | Engineered heterodimeric protein domains |
| US20080014196A1 (en) * | 2006-06-06 | 2008-01-17 | Genentech, Inc. | Compositions and methods for modulating vascular development |
| CA2654000A1 (en) | 2006-06-06 | 2008-05-22 | Genentech, Inc. | Anti-dll4 antibodies and methods using same |
| PL2032166T3 (pl) * | 2006-06-13 | 2013-09-30 | Oncomed Pharm Inc | Kompozycje i sposoby diagnozowania i leczenia nowotworów |
| WO2007147901A1 (en) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
| CA2660235C (en) | 2006-08-07 | 2015-09-22 | Regeneron Pharmaceuticals, Inc. | Therapeutic methods for treating vascular eye disorders with dll4 antagonists |
| ES2399075T3 (es) * | 2006-08-30 | 2013-03-25 | Genentech, Inc. | Anticuerpos multiespecíficos |
| US7750124B2 (en) | 2006-09-29 | 2010-07-06 | Oncomed Pharmaceuticals, Inc. | Anti-human DLL4 antibodies and compositions |
| US20110076279A1 (en) * | 2006-10-20 | 2011-03-31 | Schering Corporation | Fully human anti-vegf antibodies and methods of using |
| US20100166746A1 (en) | 2006-12-04 | 2010-07-01 | Medlmmune Way | High potency recombinant antibodies, methods for producing them and use in cancer therapy |
| WO2008073509A2 (en) * | 2006-12-11 | 2008-06-19 | Genentech, Inc. | Compositions and methods for treating a neoplasm |
| NO347649B1 (no) * | 2006-12-14 | 2024-02-12 | Regeneron Pharma | Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse. |
| ES2582656T3 (es) * | 2006-12-19 | 2016-09-14 | Genentech, Inc. | Antagonistas específicos del VEGF para terapia adyuvante y neoadyuvante, y el tratamiento de tumores en fase temprana |
| EP2120996A2 (en) | 2006-12-20 | 2009-11-25 | Vasgene Therapeutics, Inc. | Methods for using and identifying modulators of delta-like 4 |
| US20100119526A1 (en) | 2007-01-26 | 2010-05-13 | Bioinvent International Ab | DLL4 Signaling Inhibitors and Uses Thereof |
| WO2008137318A1 (en) | 2007-05-04 | 2008-11-13 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating disorders associated with salt or fluid retention |
| GB0709333D0 (en) | 2007-05-15 | 2007-06-20 | Smart Targeting Ltd | Binding protein |
| CA2702637A1 (en) * | 2007-10-22 | 2009-04-30 | Schering Corporation | Fully human anti-vegf antibodies and methods of using |
| AU2008315414A1 (en) * | 2007-10-25 | 2009-04-30 | Philogene, Inc. | Antibodies specific to pro-angiogenic isoforms of vascular endothelial growth factor (VEGF) |
| WO2009075565A1 (en) | 2007-12-12 | 2009-06-18 | Erasmus University Medical Center Rotterdam | Methods for controlling vasculogenesis |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| PT2235064E (pt) | 2008-01-07 | 2016-03-01 | Amgen Inc | Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática |
| CN102076355B (zh) * | 2008-04-29 | 2014-05-07 | Abbvie公司 | 双重可变结构域免疫球蛋白及其用途 |
| US20100260668A1 (en) | 2008-04-29 | 2010-10-14 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
| EP2356270B1 (en) | 2008-11-07 | 2016-08-24 | Fabrus Llc | Combinatorial antibody libraries and uses thereof |
| CN103396487A (zh) * | 2008-12-12 | 2013-11-20 | 贝林格尔.英格海姆国际有限公司 | 抗igf抗体 |
| SG175289A1 (en) * | 2009-04-20 | 2011-11-28 | Genentech Inc | Adjuvant cancer therapy |
| WO2010124009A2 (en) | 2009-04-21 | 2010-10-28 | Schering Corporation | Fully human anti-vegf antibodies and methods of using |
| CN102459346B (zh) * | 2009-04-27 | 2016-10-26 | 昂考梅德药品有限公司 | 制造异源多聚体分子的方法 |
| AU2010270844A1 (en) * | 2009-07-08 | 2011-12-22 | Amgen Inc. | Design of stable and aggregation free antibody Fc molecules through CH3 domain interface engineering |
| US20110172398A1 (en) | 2009-10-02 | 2011-07-14 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules for anti-angiogenesis therapy |
| EP3485908B1 (en) | 2009-10-16 | 2021-08-18 | Mereo BioPharma 5, Inc. | Therapeutic combination and use of dll4 antagonist antibodies and anti-hypertensive agents |
| WO2011047442A1 (en) | 2009-10-23 | 2011-04-28 | Garvan Institute Of Medical Research | Modified variable domain molecules and methods for producing and using same |
| WO2011068840A1 (en) * | 2009-12-01 | 2011-06-09 | Oncomed Pharmaceuticals, Inc. | Methods for treating cancers comprising k-ras mutations |
| US8551715B2 (en) | 2010-02-12 | 2013-10-08 | Oncomed Pharmaceuticals, Inc. | Methods for identifying and isolating cells expressing a polypeptide |
| SG10201501562VA (en) | 2010-03-02 | 2015-04-29 | Abbvie Inc | Therapeutic dll4 binding proteins |
| US20130323265A1 (en) | 2010-11-15 | 2013-12-05 | Oncomed Pharmaceuticals, Inc. | Methods for treating cancer with dll4 antagonists |
| CN106167526A (zh) | 2011-07-15 | 2016-11-30 | 昂考梅德药品有限公司 | Rspo结合剂和其应用 |
| HRP20190044T1 (hr) | 2011-09-23 | 2019-02-22 | Oncomed Pharmaceuticals, Inc. | Agensi koji vežu vegf/dll4 i njihove uporabe |
| CA2878868A1 (en) | 2012-07-13 | 2014-01-16 | Austin L. Gurney | Rspo3 binding agents and uses thereof |
| AU2013337811A1 (en) | 2012-10-31 | 2015-05-14 | Oncomed Pharmaceuticals, Inc. | Methods and monitoring of treatment with a DLL4 antagonist |
-
2007
- 2007-09-28 US US11/905,392 patent/US7750124B2/en active Active
- 2007-09-28 PL PL07838966T patent/PL2066694T3/pl unknown
- 2007-09-28 WO PCT/US2007/020889 patent/WO2008042236A2/en not_active Ceased
- 2007-09-28 ES ES07838966.5T patent/ES2557953T3/es active Active
- 2007-09-28 RS RS20160035A patent/RS54452B1/sr unknown
- 2007-09-28 MX MX2009003229A patent/MX2009003229A/es active IP Right Grant
- 2007-09-28 AU AU2007305443A patent/AU2007305443B2/en active Active
- 2007-09-28 DK DK07838966.5T patent/DK2066694T3/en active
- 2007-09-28 SI SI200731729T patent/SI2066694T1/sl unknown
- 2007-09-28 HU HUE07838966A patent/HUE028379T2/en unknown
- 2007-09-28 KR KR1020097008735A patent/KR101477824B1/ko not_active Expired - Fee Related
- 2007-09-28 EP EP12185260A patent/EP2562188A3/en not_active Withdrawn
- 2007-09-28 PT PT78389665T patent/PT2066694E/pt unknown
- 2007-09-28 CA CA2664738A patent/CA2664738C/en active Active
- 2007-09-28 HR HRP20160082TT patent/HRP20160082T1/hr unknown
- 2007-09-28 JP JP2009530419A patent/JP5535633B2/ja not_active Expired - Fee Related
- 2007-09-28 ME MEP-2016-8A patent/ME02371B/me unknown
- 2007-09-28 EP EP07838966.5A patent/EP2066694B1/en active Active
- 2007-09-28 EP EP17205290.4A patent/EP3357932A1/en not_active Withdrawn
- 2007-09-28 BR BRPI0717431-4A patent/BRPI0717431A2/pt not_active IP Right Cessation
- 2007-09-28 NZ NZ576404A patent/NZ576404A/en unknown
- 2007-09-28 EA EA200970335A patent/EA018260B1/ru not_active IP Right Cessation
-
2009
- 2009-03-06 ZA ZA2009/01615A patent/ZA200901615B/en unknown
- 2009-03-18 CR CR10667A patent/CR10667A/es not_active Application Discontinuation
- 2009-03-19 IL IL197721A patent/IL197721A/en active IP Right Grant
- 2009-03-26 CO CO09031240A patent/CO6180466A2/es active IP Right Grant
- 2009-04-22 MA MA31810A patent/MA30808B1/fr unknown
- 2009-04-24 NO NO20091635A patent/NO20091635L/no not_active Application Discontinuation
-
2010
- 2010-05-18 US US12/782,429 patent/US9376497B2/en active Active
-
2013
- 2013-03-14 US US13/826,103 patent/US9228020B2/en active Active
-
2014
- 2014-03-06 JP JP2014043403A patent/JP5997194B2/ja not_active Expired - Fee Related
-
2016
- 2016-01-21 CY CY20161100065T patent/CY1117154T1/el unknown
- 2016-05-27 US US15/167,510 patent/US20160367667A1/en not_active Abandoned
- 2016-08-25 JP JP2016164264A patent/JP2017002076A/ja active Pending
-
2018
- 2018-08-24 US US16/111,841 patent/US20190060453A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014158469A5 (enExample) | ||
| ME02371B (me) | Sastojci i postupci za dijagnstikovanje i tretman raka | |
| JP2018508483A5 (enExample) | ||
| JP2018503365A5 (enExample) | ||
| JP2018527919A5 (enExample) | ||
| JP2020528750A5 (enExample) | ||
| JP2017514461A5 (enExample) | ||
| JP2017507900A5 (enExample) | ||
| JP2010504755A5 (enExample) | ||
| RU2016137110A (ru) | Антитела к компоненту комплемента с5 | |
| JP2015529641A5 (enExample) | ||
| JP2013502913A5 (enExample) | ||
| JP2014511179A5 (enExample) | ||
| HRP20221226T1 (hr) | Protutijela protiv pd-1 i postupci njihove upotrebe | |
| CN109311978B (zh) | Dsg2单克隆抗体和其用途 | |
| JP2019526622A5 (enExample) | ||
| JP2018534933A5 (enExample) | ||
| JP2017535257A5 (enExample) | ||
| RU2013102225A (ru) | АНТИТЕЛА ПРОТИВ Axl И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| RU2017119543A (ru) | Анти-tim3 антитела и способы их применения | |
| JP2017506217A5 (enExample) | ||
| JP2011514150A5 (enExample) | ||
| JP2017529838A5 (enExample) | ||
| JP2013538553A5 (enExample) | ||
| JP2015500207A5 (enExample) |